Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation.
Rebecca E ColmanAurélien MaceMarva SeifertJonathan HetzelHaifa MshaielAnita SureshDarrin LemmerDavid M EngelthalerDonald G CatanzaroAmanda G YoungClaudia M DenkingerTimothy C RodwellPublished in: PLoS medicine (2019)
The iSeq100 instrument is capable of running existing TB WGS and targeted NGS library preparations with comparable accuracy to the MiSeq. The iSeq100 has reduced sequencing workflow hands-on time and is able to deliver sequencing results in <24 hours. Reduced capital and maintenance costs and lower-throughput capabilities also give the iSeq100 an advantage over MiSeq in settings of individualized care but not in high-throughput settings such as reference laboratories, where sample batching can be optimized to minimize cost at the expense of workflow complexity and time.
Keyphrases
- drug resistant
- mycobacterium tuberculosis
- single cell
- high throughput
- multidrug resistant
- acinetobacter baumannii
- cancer therapy
- healthcare
- electronic health record
- palliative care
- drug delivery
- pulmonary tuberculosis
- pseudomonas aeruginosa
- pain management
- high intensity
- patient reported outcomes
- cystic fibrosis
- affordable care act